Literature DB >> 31403866

Management of Rare Ovarian Cancer Histologies.

David M Gershenson1, Aikou Okamoto2, Isabelle Ray-Coquard3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31403866     DOI： 10.1200/JCO.18.02419

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Oncological and Reproductive Outcomes in Patients With Advanced-Stage Ovarian Immature Teratoma: Experience From a Tertiary Center.

Authors:  Dan Wang; Wei Cang; Shan Zhu; Congwei Jia; Dongyan Cao; Jiaxin Yang; Yang Xiang
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

2.  Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases.

Authors:  Tanja Pejovic; Pierre-Valérien Abate; Hongli Ma; Jaclyn Thiessen; Christopher L Corless; Abigail Peterson; Hugues Allard-Chamard; Marilyne Labrie
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

3.  Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.

Authors:  Toshiyuki Seki; Nozomu Yanaihara; Jason Solomon Shapiro; Misato Saito; Junya Tabata; Ryo Yokomizo; Daito Noguchi; Takafumi Kuroda; Ayako Kawabata; Jiro Suzuki; Kazuaki Takahashi; Haruka Matsuzawa; Misayo Miyake; Masataka Takenaka; Yasushi Iida; Satoshi Yanagida; Aikou Okamoto
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

4.  Misdiagnosed appendiceal mucinous neoplasms and primary ovarian mucinous tumors present with different pre- and intraoperative characteristics.

Authors:  Yi Yu; Tao Wang; Zhen Yuan; Wei Lin; Jiaxin Yang; Dongyan Cao
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

Review 5.  Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.

Authors:  Asaf Maoz; Koji Matsuo; Marcia A Ciccone; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson
Journal:  Cancers (Basel)       Date:  2020-05-29       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.